Zydus Life arm Zydus Lifesciences Global FZE inks licensing and supply deal with MSN for tablets used to treat advanced kidney cancer

[{ "selector": ".fxnfs-a", "duration": "500ms", "fill": "forwards", "delay": "0ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }]

The deal inked an exclusive licensing and supply agreement with MSN Laboratories for the US market to supply Cabozantinib tablets, which treat advanced kidney cancer.

[{ "selector": ".norku-a", "duration": "900ms", "fill": "forwards", "delay": "200ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }, { "selector": ".djmpi-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 448px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".sbwoi-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 455px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }]

MSN Lab will be in charge of manufacturing and supplying the generic version of the CABOMETYX drug.

[{ "selector": ".badpi-a", "duration": "900ms", "fill": "forwards", "delay": "200ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }, { "selector": ".wzzra-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 448px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".dtxdb-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 455px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }] Company Details

Zydus Lifesciences Global FZE will distribute and sell the product in the US market

[{ "selector": ".gwdma-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 448px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".nrjga-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 455px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".gbxgd-a", "duration": "900ms", "fill": "forwards", "delay": "200ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }]

The total addressable opportunity of Cabozantinib tablets in the US is approximately $1,464 million, as per IQVIA MAT Mar 2024.

[{ "selector": ".sjgnu-a", "duration": "900ms", "fill": "forwards", "delay": "200ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }, { "selector": ".upoqp-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 448px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".laejl-a", "duration": "500ms", "fill": "forwards", "delay": "900ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 455px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }]